Pernix Therapeutics Launches Generic Version of Treximet by Company’s Subsidiary, Macoven Pharmaceuticals

Pharmaceutical Investing

Pernix Therapeutics (NASDAQ:PTX), a specialty pharmaceutical company, announced the launch of an authorized generic version of Treximet® (sumatriptan/naproxen sodium) in the U.S. by the Company’s subsidiary, Macoven Pharmaceuticals, LLC. Treximet is a prescription medicine that contains sumatriptan and naproxen sodium (a NSAID) and is indicated for the treatment of acute migraine headaches with or without …

As quoted in the press release:

“The availability of both a branded and authorized generic version of Treximet demonstrates that Pernix continues to view Treximet as an important part of its business,” said John Sedor, Pernix’s Chairman and Chief Executive Officer. “Through our launch of an authorized generic version of Treximet, Pernix is providing patients and providers with access to a lower-cost treatment for acute migraine headaches.”

Click here to read the full press release.

generic migraine patients specialty pharmaceutical specialty pharmaceutical company therapeutics Pharmaceutical Investing